| You are here: Home: BCU 6|2004: Daniel F Hayes, MD: Select publications
Select Publications
Braun S et al. Pooled analysis of prognostic impact of bone marrow micrometastasis: 10-year survival of 4199 breast cancer patients. Breast Cancer Res Treat 2003;Abstract 7.
Buchholz TA et al. Lack of bcl-2 and bax expression correlates with pathological complete response to doxorubicin-based neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2003;Abstract 308.
Dontu G et al. In vitro propagation and transcriptional profiling of human mammary stem/ progenitor cells. Genes Dev 2003;17(10):1253-70. Abstract
Dontu G et al. Stem cells in normal breast development and breast cancer. Cell Prolif 2003;36(Suppl 1):59-72. Abstract
Esteban J et al. Tumor gene expression and prognosis in breast cancer: Multi-gene RT-PCR assay of paraffin-embedded tissue. Proc ASCO 2003;Abstract 3416.
Hannemann J et al. Changes in gene expression profiling due to primary chemotherapy in patients with locally advanced breast cancer. Proc ASCO 2004;Abstract 502.
Jones S et al. Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat 2003;Abstract 10.
Klijn JG et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 2001;19(2):343-53. Abstract
Paik S et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients — NSABP studies B-20 and B-14. Breast Cancer Res Treat 2003;82(Suppl 1):10; Abstract 16.
Pusztai L et al. Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. Proc ASCO 2003;Abstract 1.
Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract
Schott AF et al. Individualized chemotherapy dosing based on metabolic phenotype. Proc ASCO 2001;Abstract 306.
Stearns V et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95(23):1758-64. Abstract
van de Vijver M et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009. Abstract
|
